Search clinical trials for: BMS-903452

Total 3168 results

National Cancer Institute (NCI)

Completed

Rebeccamycin Analogue in Treating Women With Stage IIIB or Stage IV Breast Cancer

Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Recurrent Breast Cancer

United States
National Cancer Institute (NCI)

Completed

Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia

Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) and other conditions

United States
Radboud University Medical Center
Bristol-Myers Squibb

Active, not recruiting

Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer (INSPIRE)

Prostatic Neoplasms, Castration-Resistant

Netherlands
Kristen Ganjoo
Bristol-Myers Squibb

Completed

Ipilimumab + Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue Sarcoma

Soft Tissue Sarcoma

United States
Exelixis

Active, not recruiting

Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (COSMIC-313)

Renal Cell Carcinoma

United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Czechia, Finland, France, Germany, Hong Kong, Hungary, Israel, Italy, Korea, Republic of, Mexico, Netherlands, New Zealand, Poland, Singapore, Spain, Taiwan, United...
Bristol-Myers Squibb

Active, not recruiting

A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma (RELATIVITY-098)

Melanoma

United States, Italy, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czechia, Denmark, Finland, France, Germany, Greece, Israel, Mexico, Norway, Romania, Spain, Sweden, Switzerland, United Kingdom
Bristol-Myers Squibb

Completed

An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread

Advanced Cancer

United States, Canada, Italy, Netherlands, Spain, Israel
Bristol-Myers Squibb

Completed

Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia (MAGNITUDE)

Hepatitis C Virus

Australia, France, United States, Spain, Italy, Netherlands, Romania, Russian Federation
Ascensia Diabetes Care

Completed

Evaluation of Blood Glucose Meter Systems

Diabetes

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Deep Vein Thrombosis | Pulmonary Embolism | Metastatic Malignant Solid Neoplasm | Cerebral Vein Thrombosis | Splanchnic Vein Thrombosis

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986337 When Taken by Mouth by Healthy Participants

Healthy Volunteers

Netherlands
Bristol-Myers Squibb

Completed

A Study to Evaluate the Drug Levels of BMS-986166 in Healthy Male Participants

Healthy Participants

United States
Bristol-Myers Squibb
AbbVie

Completed

Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma

Smoldering Multiple Myeloma

United States
Bristol-Myers Squibb

Completed

Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer

Head and Neck Cancer | Colorectal Cancer

United States
Bristol-Myers Squibb

Completed

The Effect of BMS-986142 on the Pharmacokinetics of a Combined Oral Contraceptive (OC) Containing Ethinyl Estradiol (EE) and Norethindrone Acetate (NET) in Healthy Female Subjects

Arthritis

United States
Bristol-Myers Squibb

Completed

Pacemaker Holter Assessment of the Effect of BMS-914392 on Atrial Fibrillation Burden

Atrial Fibrillation

United Kingdom
Bristol-Myers Squibb

Completed

Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV (ALLY 3)

Hepatitis C

United States, Puerto Rico
Bristol-Myers Squibb

Completed

Continue Entecavir Rollover From China

Chronic Hepatitis B Virus
Virginia Commonwealth University
National Institute on Disability, Independent Living, and Rehabilitation... and other collaborators

Recruiting

Transspinal Stimulation With and Without Blood Flow Restricted Exercise Via Telehealth in Persons With Tetraplegia (SCIMS Main)

Tetraplegia/Tetraparesis

United States
University of California, Berkeley
National Heart, Lung, and Blood Institute (NHLBI)

Completed

BMI Screening and Reporting in Schools: The Fit Study

Overweight | Pediatric Obesity

United States
Charite University, Berlin, Germany
miha bodytec GmbH; Sonnenfeld-Stiftung; Robert-Enke-Stiftung

Active, not recruiting

Empowering Health: Acute Psychological Effects of an Electromyostimulation-Whole-Body-Workout

Depression

Germany
Hoffmann-La Roche

Completed

Accu-Chek® CONNECT at School (CATS) Pediatric Study (CATS)

Diabetes Mellitus, Type 1

United States
Ottawa Hospital Research Institute

Completed

Does Contextual Interference Improve Retention of Basic Life Support Skills? A Randomized Controlled Trial

Cardiopulmonary Resuscitation | Basic Life Saving Skills | Skill Retention

Canada
M.D. Anderson Cancer Center

Recruiting

Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.

Renal Cell Carcinoma

United States
Ascensia Diabetes Care

Completed

Comparison Evaluation of Blood Glucose Meter Systems

Diabetes

United States
National Cancer Institute (NCI)

Active, not recruiting

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

Soft Tissue Sarcoma | Renal Cell Carcinoma | Hepatocellular Carcinoma | Osteosarcoma | Ewing Sarcoma | Recurrent Renal Cell Carcinoma | Refractory Malignant Solid Neoplasm | Rhabdomyosarcoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Malignant Solid Neoplasm | Recurrent Osteosarcoma | Recurrent... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma

Recurrent Ewing Sarcoma | Recurrent Osteosarcoma | Stage III Osteosarcoma AJCC v7 | Stage IV Osteosarcoma AJCC v7 | Stage IVA Osteosarcoma AJCC v7 | Stage IVB Osteosarcoma AJCC v7 | Metastatic Osteosarcoma | Metastatic Ewing Sarcoma | Unresectable Ewing Sarcoma | Unresectable Osteosarcoma

France
Bristol-Myers Squibb

Terminated

Safety, Pharmacokinetics and Pharmacodynamics of BMS-936559 in Severe Sepsis

Septic Shock | Severe Sepsis

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects

Ischemic Stroke

United States
AstraZeneca

Completed

Bioequivalence/Food Effect - Saxa/Dapa Dual Fixed Dose Combination (FDC)

Type 2 Diabetes Mellitus
Bristol-Myers Squibb

Terminated

A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder (CheckMate 9UT)

Urinary Bladder Neoplasms

United States, Argentina, Australia, Brazil, Canada, Chile, China, France, Mexico, Netherlands, Spain, United Kingdom, Italy, Hong Kong, Russian Federation
R-Pharm

Completed

Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast Cancer

Metastatic Breast Cancer | Triple Negative Locally Advanced Non-resectable Breast Cancer

Czech Republic, Italy, Poland, Spain, Austria, France, Greece
BioMarin Pharmaceutical

Recruiting

A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema (HAErmony-1)

Hereditary Angioedema | HAE

United States, Spain, Australia
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) & Beta-thalassemia (β-Thal) in India

Anemia

India
Bristol-Myers Squibb
Nitto Denko Corporation

Completed

Phase 1b/2, Open Label, Repeat Dose, Dose Escalation Study of ND-L02-s0201 Injection in Subjects With Moderate to Extensive Fibrosis (METAVIR F3-4)

Moderate to Extensive Hepatic Fibrosis (METAVIR F3-4)

Bulgaria, United States
Bristol-Myers Squibb

Completed

A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.

Hepatitis C

United States
Bristol-Myers Squibb

Completed

A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse (BMS TIME-1)

Multiple Myeloma

United States, Canada
Bristol-Myers Squibb

Completed

A Study in Japan of the Safety and Antiviral Activity With Chronic Hepatitis B Infection

Chronic Hepatitis B
Ascensia Diabetes Care

Completed

Evaluation of Blood Glucose Monitoring Systems With Blood Samples From Neonates

Diabetes

United States
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Active, not recruiting

Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer (CheckMate901)

Urothelial Cancer

Russian Federation, United States, Brazil, Spain, Chile, Korea, Republic of, Argentina, Australia, Canada, China, Czechia, Denmark, Finland, France, Germany, Greece, Israel, Italy, Japan, Mexico, Netherlands, Norway, Peru, Poland, Romania, Swed... and more
Bristol-Myers Squibb

Completed

A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer

Prostatic Neoplasms, Castration-Resistant

United States, Argentina, Canada, France, Greece, Italy, Netherlands, United Kingdom
Bristol-Myers Squibb

Terminated

A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors

Cancer | Neoplasm | Tumors | Malignancy

United States, Canada, Spain, Switzerland
University of Zurich
Foundation Wings For Life

Active, not recruiting

Body Weight Supported Training Study

Spinal Cord Diseases

Switzerland
Universidad de León

Completed

Dynamic Electrostimulation on the Abdominal Muscles in Healthy Individuals

Healthy

Spain
Bristol-Myers Squibb

Completed

An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers

Lung Cancer

Italy, United States, France, Russian Federation, Spain, Argentina, Belgium, Brazil, Canada, Chile, Czechia, Germany, Greece, Hungary, Mexico, Netherlands, Poland, Romania, Switzerland, Turkey, United Kingdom
Bristol-Myers Squibb

Active, not recruiting

A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors

United States, Spain, Italy, Canada, Germany, United Kingdom, Denmark, Finland
ViiV Healthcare
GlaxoSmithKline

Completed

Absolute Bioavailability of BMS-626529 After Oral and Intravenous Dosing

Infection, Human Immunodeficiency Virus

United Kingdom
Bristol-Myers Squibb
Roche-Genentech

Terminated

Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)

Melanoma

United States
Bristol-Myers Squibb

Completed

Safety Study of BMS-823778 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2

Canada, Australia, United States
Bristol-Myers Squibb

Completed

Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment (BRISK PS)

Liver Cancer

United States, Argentina, Brazil, Canada, China, France, Germany, Hong Kong, India, Italy, Japan, Korea, Republic of, Mexico, Puerto Rico, Russian Federation, Taiwan, Spain, Belgium, Greece

Search clinical trials for: BMS-903452

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cambodia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations